Fairmount Funds Management LLC's Increased Stake in Spyre Therapeutics

Fairmount Funds Management LLC has filed an amendment to its Schedule 13D, reporting an increased stake in Spyre Therapeutics, Inc. The filing indicates that Fairmount now holds 7,272,341 shares of common stock, representing an 8.99% ownership in the company. This marks a significant increase from previous filings, with the value of the holdings rising by 168.88% to $161,736,863.84. The amendment also details a lock-up agreement entered into by Fairmount Healthcare Fund II L.P. in connection with Spyre Therapeutics' recent public offering, restricting the sale of shares for 60 days post-offering. The filing underscores Fairmount's continued investment in Spyre Therapeutics and its commitment to the company's growth.